In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH -Mutant Diffuse Gliomas - Sorbonne Université Access content directly
Journal Articles Neurology Year : 2022

In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH -Mutant Diffuse Gliomas

Clément Pontoizeau
Chris Ottolenghi

Abstract

Background and Objectives D-2-hydroxyglutarate (2HG) characterizes IDH -mutant gliomas and can be detected and quantified with edited MRS (MEGA-PRESS). In this study, we investigated the clinical, radiologic, and molecular parameters affecting 2HG levels. Methods MEGA-PRESS data were acquired in 71 patients with glioma (24 untreated, 47 treated) on a 3 T system. Eighteen patients were followed during cytotoxic (n = 12) or targeted (n = 6) therapy. 2HG was measured in tumor samples using gas chromatography coupled to mass spectrometry (GCMS). Results MEGA-PRESS detected 2HG with a sensitivity of 95% in untreated patients and 62% in treated patients. Sensitivity depended on tumor volume (>27 cm 3 ; p = 0.02), voxel coverage (>75%; p = 0.002), and expansive presentation (defined by equal size of T 1 and FLAIR abnormalities, p = 0.04). 2HG levels were positively correlated with IDH -mutant allelic fraction ( p = 0.03) and total choline levels ( p < 0.001) and were higher in IDH2 -mutant compared with IDH1 R132H -mutant and non–R132H IDH1 -mutant patients ( p = 0.002). In patients receiving IDH inhibitors, 2HG levels decreased within a few days, demonstrating the on-target effect of the drug, but 2HG level decrease did not predict tumor response. Patients receiving cytotoxic treatments showed a slower decrease in 2HG levels, consistent with tumor response and occurring before any tumor volume change on conventional MRI. At progression, 1p/19q codeleted gliomas, but not the non-codeleted, showed detectable in vivo 2HG levels, pointing out to different modes of progression characterizing these 2 entities. Discussion MEGA-PRESS edited MRS allows in vivo monitoring of 2-hydroxyglutarate, confirming efficacy of IDH inhibition and suggests different patterns of tumor progression in astrocytomas compared with oligodendrogliomas.
Fichier principal
Vignette du fichier
IDASPE_21052022_revised_clean.pdf (302.95 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04056879 , version 1 (03-04-2023)

Identifiers

Cite

Anna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, Romain Valabregue, Mehdi Touat, et al.. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH -Mutant Diffuse Gliomas. Neurology, 2022, 100 (1), pp.e94-e106. ⟨10.1212/WNL.0000000000201137⟩. ⟨hal-04056879⟩
37 View
43 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More